PIM
CYTK icon

Platinum Investment Management’s Cytokinetics CYTK Stock Holding History

Platinum Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,478
Closed -$784K – 134
2024
Q2 		$784K Sell
14,478
-1,648
-10% -$99.5K 0.03% 84
2024
Q1 		$1.13M Sell
16,126
-3,012
-16% -$233K 0.05% 86
2023
Q4 		$1.6M Buy
+19,138
New +$693K 0.06% 85

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Platinum Investment Management's CYTK Position: Q3 2024 in Review

Platinum Investment Management sold out of Cytokinetics (CYTK) in Q3 2024, closing a stake of 14,478 shares — an estimated $784K sold.

Platinum Investment Management first reported a position in CYTK in Q4 2023 and held it in 3 quarters. The position peaked at $1.6M in Q4 2023. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

  • Platinum Investment Management reported no remaining Cytokinetics position as of Q3 2024 after selling out during the quarter.
  • Platinum Investment Management sold 14,478 Cytokinetics shares in Q3 2024, an estimated $784K.
  • Platinum Investment Management first reported a position in Cytokinetics in Q4 2023 and held it in 3 quarters.
  • Platinum Investment Management's Cytokinetics position peaked at $1.6M in Q4 2023.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on Platinum Investment Management's 13F filing for Q3 2024, filed 8 Nov 2024.